Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Update

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 457,500 shares, an increase of 90.3% from the December 31st total of 240,400 shares. Approximately 3.2% of the shares of the stock are sold short. Based on an average trading volume of 3,640,000 shares, the short-interest ratio is currently 0.1 days.

Institutional Investors Weigh In On Virpax Pharmaceuticals

An institutional investor recently bought a new position in Virpax Pharmaceuticals stock. Garden State Investment Advisory Services LLC purchased a new position in shares of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 57,300 shares of the company’s stock, valued at approximately $40,000. Garden State Investment Advisory Services LLC owned 1.17% of Virpax Pharmaceuticals as of its most recent SEC filing. 32.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Maxim Group restated a “hold” rating on shares of Virpax Pharmaceuticals in a report on Wednesday, October 9th.

Virpax Pharmaceuticals Trading Down 3.5 %

Shares of VRPX stock traded down $0.01 during mid-day trading on Thursday, reaching $0.31. The stock had a trading volume of 510,607 shares, compared to its average volume of 520,959. Virpax Pharmaceuticals has a 12-month low of $0.23 and a 12-month high of $5.48. The business has a 50-day simple moving average of $0.37 and a 200 day simple moving average of $0.68.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.